REQUEST A DEMO
总计
USD $0.00
搜索更多公司

Universe Pharmaceuticals Inc. (中国)

主营业务: 医药制剂制造
全名: Universe Pharmaceuticals Inc. 公司更新日期: 2025.07.15
购买我们的报告为这家公司 USD 29.95 最近财务数据:2024 可有的: 英语 & 中文 下载示例的报告

The Company engages in the manufacture, marketing, distribution, and sale of traditional Chinese medicine derivative products in China.
The Company offers products for the treatment and relief of common chronic health conditions in the elderly for physical wellness and longevity; and cold and flu medications. The company also distributes and sells third-party products, including biomedical drugs, medical instruments, traditional Chinese medicine pieces, and dietary supplements. Its customers include pharmaceutical companies, hospitals, clinics, and drugstore chains.
The Company has one operating segment.
HISTORY
1998 The company was founded.
2010 The Company formed in 2010, a wholly-owned subsidiary of Jiangxi Universe.
2014 The Companys wholly owned subsidiary Universe HK was formed in Hong Kong on May 21, 2014.
2019 The Companys wholly foreign owned enterprise incorporated in China on Aril 8, 2019.
2021 The Company s common stock is listed on NASDAQ under the symbol UPC.

总部
265 Jingjiu Avenue, Jinggangshan Economic And Technological Development Zone
吉安; 江西; 邮编: 343100

联系方式: 购买Universe Pharmaceuticals Inc.报告以查看信息。

网站: http://www.universe-pharmacy.com

基本信息
员工总数:
购买Universe Pharmaceuticals Inc.报告以查看信息。
流通股:
购买Universe Pharmaceuticals Inc.报告以查看信息。
财务审计师:
购买Universe Pharmaceuticals Inc.报告以查看信息。
成立日期:
2025.12.06
主要管理人员
购买此报告以查看信息。
Chairman
购买此报告以查看信息。
Chief Financial Officer
购买此报告以查看信息。
Chief Operating Officer
购买此报告以查看信息。
Director/Member of the Board
购买此报告以查看信息。
Outside Director
所有权明细
购买此报告以查看信息。
0.615%
购买此报告以查看信息。
下属公司
Jiangxi Universe Pharmaceuticals Co., Ltd.
Jiangxi Universe Pharmaceuticals Commercial Trade Co., Ltd.
Jiangxi Universe Pharmaceuticals Technology Co., Ltd.
公司业绩
图表中的财务价值可在之后获得Universe Pharmaceuticals Inc.报告购买。
寻找的不仅仅是一个公司的报告吗?

EMIS公司简介是一个更大的信息服务的一部分,它结合了公司,行业和国家数据和分析在超过125个新兴市场.

请求EMIS服务的演示
主要财务重点
年增长百分比对于以当地货币近两年CNY。绝对财务数据包含在购买报告中。
销售净额
-28.23%
营业收入总计
-28.23%
营业利润
-100.79%
EBITDA
-39.29%
净利润(亏损)
74.67%
总资产
65.1%
权益总额
108.77%
经营利润率
-22.16%
销售收益率
65.79%
股本收益率
43.04%
负债股权比率
-10.33%
速动比率
1.16%
现金比率
1.59%

查看更多信息, 申请试用

购买这家公司报告
需要定期访问公司,行业或国家/地区的信息吗?